- Outpatient Treatment With Anti-Coronavirus Immunoglobulin — Recruiting • Phase III • Respiratory / COPD / Asthma • NCT04910269.
- What is being tested: A single infusion of anti-COVID-19 hyperimmune intravenous immunoglobulin (hIVIG) compared to placebo in recently diagnosed COVID-19 patients, evaluating both safety and efficacy in an outpatient setting.
- Patient eligibility overview: Adults with recently diagnosed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection who are suitable for outpatient management, allowing assessment across a spectrum of disease severity in community-based settings.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
The primary objective of the Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC) (INSIGHT 012) trial is to compare the safety and efficacy of a single infusion of anti-COVID-19 hyperimmune intravenous immunoglobulin (hIVIG) versus placebo among adults with recently diagnosed severe acute respiratory syndrome - coronavirus 2 (SARS-CoV2) infection who do not require hospitalization. The primary endpoint of this double-blind randomized trial is a five-category ordinal outcome that assesses the participant's clinical status seven days after the infusion of hIVIG or placebo. 1. Asymptomatic and no limitations in usual activity due to…
- : * Clinical risk based on age ≥ 55 years or an adult (age ≥ 18 years) with an immunosuppressed condition. * Positive test for SARS-CoV-2 within ≤5 days (if >1 test, the first positive is within ≤5 days). Tests may include an institutional-based nucleic acid amplification test (NAAT), or any protocol-approved rapid test. * Within ≤5 days from symptom onset, if symptomatic from current SARS-CoV-2 infection. * Agrees to not participate in another clinical trial for the treatment or management of SARS-CoV-2 infection through Day 7, or until hospitalized or significant disease progression if prior to Day 7 (defined by ordinal category 4 or 5). * Participant provides written informed consent prior to study procedures, and understands and agrees to adhere to planned study procedures through Day 28. Ongoing immunosuppressive condition or immunosuppressive treatment, includes: 1. Steroids equivalent to prednisone > 10 mg/day for at least the last 28 days 2. Rheumatologic or autoimmune disorder treated with a biologic or non-biologic immunosuppressive therapy 3. Antirejection medicine after solid organ or stem cell transplantation 4. Cancer treatment with systemic chemotherapy, biologic and/or cell-based therapy in the last 12 months 5. Primary or acquired severe B- or T-lymphocyte immune dysfunction…
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.